Neuroprotective Effect of Eco-Sustainably Extracted Grape Polyphenols in Neonatal Hypoxia-Ischemia.

Polyphenols are natural compounds with promising prophylactic and therapeutic applications. However, their methods of extraction, using organic solvents, may prove to be unsuitable for daily consumption or for certain medical indications. Here, we describe the neuroprotective effects of grape polyphenols extracted in an eco-sustainable manner in a rat model of neonatal hypoxia-ischemia (NHI). Polyphenols (resveratrol, pterostilben and viniferin) were obtained using a subcritical water extraction technology to avoid organic solvents and heavy metals associated with chemical synthesis processes. A resveratrol or a polyphenol cocktail were administered to pregnant females at a nutritional dose and different time windows, prior to induction of NHI in pups. Reduced brain edema and lesion volumes were observed in rat pups whose mothers were supplemented with polyphenols. Moreover, the preservation of motor and cognitive functions (including learning and memory) was evidenced in the same animals. Our results pave the way to the use of polyphenols to prevent brain lesions and their associated deficits that follow NHI, which is a major cause of neonatal death and disabilities.

Expression of matrix metalloproteinase-9 in prostate cancer. Preliminary experience.

OBJECTIVES: To study the validity of Matrix Metalloproteinase 9 as a complementary marker to PSA for the diagnosis and prognosis of Prostate Cancer. METHODS: Prospective study structured as a hospital-based cohort of 100 consecutive patients undergoing prostate biopsy. Serum determination of MMP-9 was carried out by means of inmunoassay. Statistical analysis was performed using the Stata/SE 8.2 software. RESULTS: 32 patients were diagnosed with prostate cancer and 52% had a Gleason score equal to or greater than 7. The values of serum MMP-9 varied between 225.7 and 1932.3 ng/ml, without significant differences among patients with benign, malignant and uncertain histology (p=0.429). The differences approached statistical significance in the subgroup of patients with PSA at 4-10 ng/ml (p=0.058), and significant differences were observed in the subgroup with free PSA to total PSA coefficient of less than 15% (p=0.037). No relationship between the Gleason score and the level of MMP-9 was shown (p=0.739). The levels of PSA and MMP-9 were shown to be independent (Pearson coefficient of correlation -0.1). CONCLUSIONS: It was not possible to show the efficacy of MMP-9 in predicting the result of the biopsy. In the group of patients with slightly increased levels of PSA (between 4 and 10 ng/ml) all the descriptive variables were higher in the group with malignant histology, though they did not reach statistical significance, they did reach significance when the coefficient of free PSA over total PSA was less than 15%, but this finding is not relevant clinically, as these patients already have a clear indication for biopsy. Neither was the relationship with the prognosis shown as there are no differences of MMP-9 expression at varying Gleason scores.

Matrix metalloproteinase- 9 polymorphisms in the diagnosis of prostate cancer. A preliminary experience.

UNLABELLED: Polymorphisms Q279R, P574R and -1562 C/T of matrix metalloproteinase-9 (MMP-9) gene have been linked with the risk of cancer and with tumoral aggressiveness in various types of cancer. So far there are no studies in the literature analysing the link between polymorphisms Q279R, P574R and -1562 C/T of MMP-9 and prostate cancer. OBJECTIVES: To establish the presence of the MMP-9's gene polymorphisms (Q279R, P574R and -1562 C/T)in relation to results of prostate biopsy, PSA values and Gleason score. METHODS: Hospital cohort of 100 patients with suspected prostate cancer, subjected to prostate biopsy, in whom the MMP-9 polymorphisms (Q279R, P574R and -1562 C/T) were analysed using the PCR-RLFP technique. RESULTS: No statistically significant differences were found in the presence of the Q279R, P574R and -1562 C/T polymorphisms in terms of prostate biopsy results (p = 0.264, p = 0.406, p = 0.860, respectively), or Gleason score (p = 0.373, p = 0.367, p = 0.476). Comparing the genotypes of the Q279R, P574R and -1562 C/T polymorphisms resulting from prostate biopsy, using subgroups according to PSA values, no statistically significant differences were found either (p = 0.332 y p = 0.393, respectively ). However, statistically significant differences were found when comparing the genotypes of the -1562 C/T polymorphism of the MMP-9 in patients showing positive biopsy for malignant tumour in comparison to a negative biopsy for a malignant tumour in the subgroup of patients with PSA 10 ng/ml (p=0.049). The joint analysis of the three MMP-9 polymorphisms, using logistical regression study did not reveal any statistically significant differences as far as the risk of developing prostate cancer is concerned based on the presence of the Q279R, P574R and -1562 C/T polymorphisms. CONCLUSION: The Q279R, P574R and -1562 C/T polymorphisms are not linked with the aggressiveness in prostate cancer, neither they are linked to the risk of suffering prostate cancer.

Expresión de metaloproteasa de matriz 9 en el cáncer de próstata. Experiencia preliminar / Expression of matrix metalloproteinase-9 in prostate cancer. Preliminary experience

OBJETIVO: Estudiar la validez de la metaloproteasa 9 (MMP-9) como marcador complementario al PSA en el diagnóstico y el pronóstico del carcinoma de próstata.MÉTODO: Estudio prospectivo estructurado como cohorte de base hospitalaria. Fueron incluidos 100 pacientes consecutivos a los que se iba a practicar una biopsia prostática. La determinación sérica de MMP-9 se realizó mediante inmunoensayo, y el análisis estadístico con el programa informático stata/SE 8.2.RESULTADOS: 32 pacientes fueron diagnosticados de carcinoma prostático y el 52% de ellos con grado Gleason mayor o igual a 7. Los valores de MMP-9 sérica oscilaron entre 225,7 y 1932,3 nanogramos por mililitro, sin encontrar diferencias estadísticamente significativas entre los pacientes con histología benigna, maligna e incierta (p=0,429). Las diferencias se acercaron a la significación estadística en el subgrupo de pacientes con PSA 4-10 ng/ml (p=0,058) y en el subgrupo PSA libre/total menor de 15% se observaron diferencias significativas (p=0,037). No se encontró relación entre el grado Gleason y el nivel de MMP-9 (p=0,739). Los niveles de PSA y MMP-9 demostraron ser independientes (Coeficiente de correlación de Pearson -0,1).CONCLUSIONES: No fue posible demostrar la eficacia de la MMP-9 para predecir el resultado de la biopsia. En el grupo de pacientes con elevaciones discretas del PSA (entre 4 y 10 ng/ml) todas las variables descriptivas fueron superiores en el grupo con histología maligna, sin alcanzar la significación estadística. Sí se alcanzó la significación cuando el cociente de PSA libre entre PSA total fue menor del 15%, pero este hallazgo no tiene relevancia en la práctica clínica, pues estos pacientes ya tienen indicación clara de biopsia. Tampoco se demuestra relación con el pronóstico al no existir diferencias de expresión de MMP-9 entre diferentes grados Gleason(AU)

OBJECTIVES: To study the validity of Matrix Metalloproteinase 9 as a complementary marker to PSA for the diagnosis and prognosis of Prostate Cancer.METHODS: Prospective study structured as a hospital-based cohort of 100 consecutive patients undergoing prostate biopsy. Serum determination of MMP-9 was carried out by means of inmunoassay . Statistical analysis was performed using the Stata/SE 8.2 software.RESULTS: 32 patients were diagnosed with prostate cancer and 52% had a Gleason score equal to or greater than 7. The values of serum MMP-9 varied between 225.7 and 1932.3 ng/ml, without significant differences among patients with benign, malignant and uncertain histology (p=0.429). The differences approached statistical significance in the subgroup of patients with PSA at 4-10 ng/ml (p=0.058), and significant differences were observed in the subgroup with free PSA to total PSA coefficient of less than 15% (p=0.037). No relationship between the Gleason score and the level of MMP-9 was shown (p=0.739). The levels of PSA and MMP-9 were shown to be independent (Pearson coefficient of correlation -0.1).CONCLUSIONS: It was not possible to show the efficacy of MMP-9 in predicting the result of the biopsy. In the group of patients with slightly increased levels of PSA (between 4 and 10 ng/ml) all the descriptive variables were higher in the group with malignant histology, though they did not reach statistical significance, they did reach significance when the coefficient of free PSA over total PSA was less than 15%, but this finding is not relevant clinically, as these patients already have a clear indication for biopsy. Neither was the relationship with the prognosis shown as there are no differences of MMP-9 expression at varying Gleason scores(AU)

Polimorfismo de la metaloproteasa de matriz 9 (MMO-9) en el diagnostico del carcinoma prostático. Experiencia preliminar / Matrix metalloproteinase 9 polyphormisms in the diagnosis of prostate cancer. A preliminary experience

Los polimorfismos Q279R, P574R y -1562 C/T en el gen de la MMP-9 se han relacionado con el riesgo de padecer cáncer y con la agresividad tumoral de varios tipos de cánceres. Hasta ahora no existen estudios en la literatura que analicen la asociación de los polimorfismos Q279R, P574R y -1562 C/T de la MMP-9 con el cáncer prostático.OBJETIVOS: Determinar las diferencias de presencia de los polimorfismos en el gen de la MMP-9 (Q279R, P574R y -1562 C/T) en función del resultado de la biopsia prostática, de las cifras del PSA y el grado histológico Gleason.MÉTODOS: Se trata de una cohorte de base hospitalaria que incluye 100 pacientes con sospecha de carcinoma prostático, sometidos a biopsia prostática, a los que se determinaron los polimorfismos de la MMP-9 (Q279R, P574R y -1562 C/T) mediante la técnica de PCR-RFLP.RESULTADOS: No se encontraron diferencias estadísticamente significativas en la presencia de los polimorfismos Q279R, P574R y -1562 C/T de la MMP-9, en función del resultado de la biopsia prostática (p = 0,264, p = 0,406, p = 0,860, respectivamente), ni en función del grado Gleason (p = 0,373, p = 0,367, p = 0,476). Al comparar los distintos genotipos de los polimorfismos Q279R y P574R de la MMP-9 en función del resultado de la biopsia prostática, haciendo subgrupos según las cifras del PSA, tampoco se encontraron diferencias estadísticamente significativas (p = 0,332 y p = 0,393, respectivamente). Se encontraron diferencias estadísticamente significativas al comparar los distintos genotipos del polimorfismo -1562 C/T de la MMP-9, en pacientes con biopsia positiva para tumor maligno respecto a biopsia negativa para tumor maligno en el subgrupo de pacientes de PSA > 10 ng/ml (p = 0,049)...(AU)

Polymorphisms Q279R, P574R and -1562 C/T of matrix metalloproteinase-9 (MMP-9) gene have been linked with the risk of cancer and with tumoral aggressiveness in various types of cancer. So far there are no studies in the literature analysing the link between polymorphisms Q279R, P574R and -1562 C/T of MMP-9 and prostate cancer.OBJECTIVES: To establish the presence of the MMP-9´s gene polymorphisms (Q279R, P574R and -1562 C/T)in relation to results of prostate biopsy, PSA values and Gleason score.METHODS: Hospital cohort of 100 patients with suspected prostate cancer, subjected to prostate biopsy, in whom the MMP-9 polymorphisms (Q279R, P574R and -1562 C/T) were analysed using the PCR-RLFP technique.RESULTS: No statistically significant differences were found in the presence of the Q279R, P574R and -1562 C/T polymorphisms in terms of prostate biopsy results (p = 0.264, p = 0.406, p = 0.860, respectively), or Gleason score (p = 0.373, p = 0.367, p = 0.476). Comparing the genotypes of the Q279R, P574R and -1562 C/T polymorphisms resulting from prostate biopsy, , using subgroups according to PSA values, no statistically significant differences were found either (p = 0.332 y p = 0.393, respectively ). However, statistically significant differences were found when comparing the genotypes of the -1562 C/T polymorphism of the MMP-9 in patients showing positive biopsy for malignant tumour in comparison to a negative biopsy for a malignant tumour in the subgroup of patients with PSA > 10 ng/ml (p=0.049). The joint analysis of the three MMP-9 polymorphisms, using logistical regression study did not reveal any statistically significant differences as far as the risk of developing prostate cancer is concerned based on the presence of the Q279R, P574R and -1562 C/T polymorphisms.CONCLUSION: The Q279R, P574R and -1562 C/T polymorphisms are not linked with the aggressiveness in prostate cancer, neither they are linked to the risk of suffering prostate cancer(AU)

Endovascular treatment of traumatic thoracic aortic injuries: short- and medium-term Follow-up.

BACKGROUND: Successful thoracic endovascular aortic repair (TEVAR) with low rates of complications has been referred to in the treatment of traumatic thoracic aortic injuries; however, we still do not know the long-term behavior. In this series, short- and intermediate-term results of TEVAR of traumatic aortic injuries are analyzed. METHODS: The clinical charts and courses of 20 patients (mean age, 31.8 years; age range, 15-65 years; 14 [70%] men) with traumatic thoracic aortic injuries treated with TEVAR were retrospectively reviewed. Mean delay from trauma to intervention was 15 days (range, 0-180 days). RESULTS: The initial success rate was 100%, with no deaths or intraoperative leaks, although in 4 (20%) patients, injuries were repaired in the arterial access site. The mean postoperative follow-up was 43.53 months (range, 5.5-108.0 months). Four (20%) patients required reintervention: 2 postoperative revascularizations of the left subclavian artery (20% of the patients in whom the ostium was intentionally occluded) and 2 aortic reinterventions (endovascular treatment of a collapsed stent graft and open repair after thrombosis of another stent graft). All reinterventions were successfully performed and no additional complications were registered during follow-up. Asymptomatic findings related to the stent graft included lack of proximal device-wall apposition in 8 patients (40%), intragraft mural thrombus formation during the first 6 months in 7 patients (35%), and an asymptomatic fracture of the longitudinal reinforcing bar of the stent graft 4 years later in 1 patient (5%). CONCLUSION: Although not completely exempt of complications, TEVAR provides a reliable method for the treatment of traumatic thoracic aortic injuries with good results in the short- and medium-term follow-up. All complications have been treated successfully. Long-term evolution of lack of proximal device-wall apposition and intragraft mural thrombus formation should be closely monitored to prevent long-term complications.

Incidence and evolution of mural thrombus in abdominal aortic endografts.

BACKGROUND: The aims of this study were to analyze the predictive factors for intragraft mural thrombus formation and evolution during follow-up after endovascular treatment of abdominal aortic aneurysms and to evaluate its relationship with the subsequent appearance of complications. METHODS: A retrospective study was performed by selecting those patients who underwent endovascular repair of an abdominal aortoiliac aneurysm between June 1998 and September 2004, with a minimum follow-up of 24 months. Preoperative clinical data, anatomical characteristics of the aneurysm, and endograft type were analyzed. In addition, clinical evaluation and abdominal computed tomography angiography (CT scans) performed at 1, 6, 12, and 24 months after the surgery were reviewed. RESULTS: Eighty-nine patients were submitted for endovascular aneurysm repair in this period, and 75 completed the 24-month follow-up. Eighteen patients developed intragraft mural thrombus (24% incidence), 13 (72.2%) appearing at 1 month of follow-up, and up to 16 (88.9%) appearing during the first 6 months. Logistic regression analysis showed that the lumen percentage of mural thrombus in the native aorta and the use of aortouniiliac endografts were independent predictors of intragraft mural thrombus formation (odds ratio, 1.065; 95% confidence interval, 1.022-1.110, and odds ratio, 8.014; 95% confidence interval, 1.598-40.181, respectively). No spontaneous regression of the thrombus was observed. The area of intragraft mural thrombus had increased at 12 and 18-24 months after their diagnosis (Wilcoxon signed rank test, p = 0.028 and 0.028, respectively). The presence of intragraft mural thrombus was associated with a greater tendency to endograft body or branch occlusion (5 of 18 cases with intragraft mural thrombus (27.8%) versus 1 of 57 cases without it (1.8%), (p = 0.003). CONCLUSION: Intragraft formation of mural thrombus is a common finding during the follow-up of abdominal aortic endografts, particularly in aneurysms with large mural thrombus of the native aorta, and is associated with the use of aortouniiliac endografts. The area occupied by the mural thrombus was shown to gradually increase during follow-up and was associated with a greater tendency for endograft occlusion.

Symptomatic collapse of a thoracic aorta endoprosthesis.

We present the case of a 40-year-old man who underwent aortic endoprosthesis implantation for a traumatic lesion of the thoracic aorta (Gore TAG, 26 x 100 mm, after the instructions for use for a thoracic aorta of 22-24 mm). At 6 months, he came to the emergency room for a hypertensive crisis and acute pulmonary edema. The chest radiograph and thoracoabdominal computed tomographic angiography study showed collapse of the endoprosthesis and a type I proximal leak. A second TAG graft was inserted within the previously collapsed device, and re-expansion was achieved, with resolution of the initial symptoms. At 3 and 6 months, the patient remained asymptomatic, and there were no new findings on computed tomographic angiography.

[Advantages and risks of the use of prostate-specific antigen (PSA) in the health-care area No. 4 of Gijon (Asturias)]. / Ventajas y riesgos de la utilización del antígeno prostático específico (PSA) en el area sanitaria v de Gijón (Asturias).

OBJECTIVES: The diagnosis of prostate cancer has changed significantly with the introduction of PSA in the clinical practice. Despite screening is under controversy the use of PSA has become widespread. The objective of this paper is to know the use of PSA in our health-care area and to analyze perceived risks and benefits. METHODS: From the informatic archives we analyze PSA determinations performed in our health-care area (290.956 citizens) over 2000 and 2001. We also analyzed prostate biopsies generated and number of cancers detected. RESULTS: 25.519 PSA determinations were performed. 59% came from general practitioners (GP), 34% from urologists and 7% from the rest of specialists. 39% are performed to men older than 70 years. PSA was normal in 78.7% of the patients and higher than 4 ng/ml in 21.2%. 488 prostatic biopsies were performed diagnosing 178 cancers (diagnostic yield 36.5%). Depending on the first PSA, diagnosis was started by a GP in 44% of the cases, a urologist in 46%, and the remaining 10% by other specialists. Mean time from first PSA to diagnosis was 5 months, without significant differences between GPs and specialities . The use of PSA by GPs is variable (between 8.1 and 45.8 determinations per 100 men over 50 years), without significant differences in prostate cancer detection by number of PSAs or differences in age. In comparison with the period 1982-1993 the incidence of prostate cancer goes from 30.76 to 52.8 new cases/100.000 inhabitants/year. There is a greater incidence and increase of cancer in the rural area (from 33.52 to 221.1 new cases/ 100.000 inhabitants/year). CONCLUSIONS: We confirm the general use of this test and the trend to screening in the primary health-care level, which participates in an important manner in the diagnosis. PSA brings forward the diagnosis of prostate cancer 5 years in our area, and shoots its incidence rates. The high use of such marker in our population of advanced age may be considered inadequate.

Ventajas y riesgos de la utilización del antígeno prostático específico (PSA) en el área sanitaria V de Gijón (Asturias) / Advantages and risk´s of the use of PSA in the health-care area Nº. 5 of Gijon (Asturias)

OBJETIVO: Con la introducción del PSAen la práctica clínica diaria, el diagnóstico del cáncerde próstata ha sufrido importantes cambios. Aunque elscreening es controvertido, su uso parece que se hageneralizado. Conocer la utilización que se hace delPSA en nuestro área sanitaria y analizar los beneficiosy riesgos que se perciben.MÉTODO: A través del archivo informático, analizamoslas determinaciones realizadas durante los años2000 y 2001 en nuestro área (290.956 habitantes).Se analizaron también las biopsias de próstata generadasy los cánceres detectados.RESULTADOS: Se realizaron 25.590 determinacionesde PSA. Proceden de Atención Primaria 59%, Urología34% y resto de especializada 7%. El 39% se realizana hombres mayores de 70 años. El PSA fue normal enel 78,7%, y mayor de 4 ng/mL en 21,2%. Se realizaron488 biopsias prostáticas, detectándose 178 carcinomas(36,5% rendimiento diagnóstico). Según el primerPSA el diagnóstico parte de primaria en 44%,Urología en 46% y resto de especializada 10%. Eltiempo medio desde el primer PSA hasta el diagnósticofue de 5 meses, sin diferencias significativas entrePrimaria y Especializada. El uso del PSA por Primariaes variable (entre 8,1 y 45,8 determinaciones porcada 100 hombres mayores de 50 años), sin diferenciassignificativas de detección de cáncer prostáticosegún número de PSAs ni diferencias de edad. Frenteal periodo 1982-1993 la incidencia de cáncer prostáticopasa de 30,76 a 52,8 nuevos casos/ 100.000habitantes/ año. Existe mayor incidencia e incrementodel cáncer en la zona rural (de 33,52 a 221,1 nuevoscasos/ 100.000 habitantes/ años).CONCLUSIONES: Confirmamos la utilización generalizadade esta prueba y la tendencia al cribado en primaria,que participa de manera importante en el diagnóstico.El PSA adelanta el diagnóstico del cáncer depróstata en 5 años en nuestro área, y dispara las tasasde incidencia de este cáncer. La elevada utilización deeste marcador en población de edad avanzada sepuede considerar inadecuada

OBJECTIVES: The diagnosis of prostatecancer has changed significantly with the introductionof PSA in the clinical practice. Despite screening isunder controversy the use of PSA has become widespread.The objective of this paper is to know the use of PSA inour health-care area and to analyze perceived risks andbenefits.METHODS: From the informatic archives we analyzePSA determinations performed in our health-care area(290.956 citizens) over 2000 and 2001. We alsoanalyzed prostate biopsies generated and number ofcancers detected.RESULTS: 25.519 PSA determinations were performed.59% came from general practitioners (GP), 34% fromurologists and 7% from the rest of specialists. 39% areperformed to men older than 70 years. PSA was normalin 78.7% of the patients and higher than 4 ng/ml in21.2%. 488 prostatic biopsies were performeddiagnosing 178 cancers (diagnostic yield 36.5%).Depending on the first PSA, diagnosis was started by aGP in 44% of the cases, a urologist in 46%, and theremaining 10% by other specialists. Mean time fromfirst PSA to diagnosis was 5 months, without significantdifferences between GPs and specialities . The use ofPSA by GPs is variable (between 8 .1 and 45.8determinations per 100 men over 50 years), withoutsignificant differences in prostate cancer detection bynumber of PSAs or differences in age. In comparisonwith the period 1982-1993 the incidence of prostatecancer goes from 30.76 to 52.8 new cases/100.000inhabitants/year. There is a greater incidence andincrease of cancer in the rural area (from 33.52 to221.1 new cases/100.000 inhabitants/year).CONCLUSIONS: We confirm the general use of thistest and the trend to screening in the primary health-carelevel, which participates in an important manner in thediagnosis. PSA brings forward the diagnosis of prostatecancer 5 years in our area, and shoots its incidencerates. The high use of such marker in our population ofadvanced age may be considered inadequate

[Cancer of the female urethra. Report of a new case a review of the literature]. / Cáncer de uretra femenino. Aportación de un nuevo caso y revisión de la literatura.

OBJECTIVE: To review the main features of female urethral cancer, the only genitourinary neoplasm with a predilection for women, the ratio being 4:1. Female urethral cancer is an uncommon neoplasm that accounts for only 0.02% of all cancers found in women. METHODS: A case of female urethral cancer in a 52-year-old woman is presented. RESULTS/CONCLUSIONS: Female urethral cancer is an uncommon neoplasm. The clinical pathologic stage is the best predictor of the disease-free survival rate. For patients with Ta-2N0M0 tumors, multimodality therapy may not be required. For patients with T3-4N0M0 tumors, the best results are obtained with multimodal radiation and chemotherapy with surgical resection.

[Neuroblastoma in adolescence. Report of a new case]. / Neuroblastoma en la adolescencia. Aportación de un nuevo caso.

OBJECTIVE: To report an uncommon case of neuroblastoma in adolescence. METHODS: A case of neuroblastoma in adolescence is presented. The etiological and pathogenetic factors, clinical and laboratory findings, behavior and treatments are discussed. RESULTS/CONCLUSIONS: Neuroblastoma and related tumors, ganglioneuroblastoma and ganglioneuroma are derived from primordial neural crest cells that migrate in the embrionary period and populate the primordial sympathetic ganglia and adrenal medulla. Neuroblastoma, the least differentiated, resembles the fetal adrenal medulla. The peak age at the time of presentation is about 18 months and only sporadic cases occur during adolescence, as the case described herein, or adult life.

Cáncer de uretra femenino. Aportación de un nuevo caso y revisión de la literatura / Female urethral cancer: Case report and literature review

Objetivos: Pretendemos revisar las características fundamentales del cáncer de uretra femenino. Es el único tumor genitourinario con predominio femenino en una relación 4:1. El cáncer de uretra es poco frecuente y representa el 0,02 por ciento de todos los tumores en la mujer.Metodos: Presentamos un caso de cáncer uretral femenino.Resultados y Conclusiones: El cáncer de uretra en la mujer es un tumor poco frecuente. El estadio clínico -patológico es el mejor predictor del intervalo libre de enfermedad/supervivencia.En estadios Ta-2N0M0 no se requiere habitualmente politerapia. En estados avanzados, los mejores resultados se obtienen tras administración de radioterapia /quimioterapia con cirugía radical (AU)

No disponible

Nuestra experiencia en adrenalectomías (1994-2000). Revisión de conjunto / Our experience with adrenalectonomy. A review of our series from 1994-2000

OBJETIVO: Presentamos 30 casos de adrenalectomía por masa suprarrenal, realizados en nuestro servicio en los últimos 6 años. MÉTODO: Un tercio de los pacientes fueron mujeres. La edad osciló entre 16 y 83 años con media de 51. En relación a la clínica presentada, el 18,5 por ciento fue un hallazgo casual, presentaron dolor abdominal o lumbar el 33,3 por ciento, síndrome de Cushing en el 18,5 por ciento,cefaleas y HTA el 18,5 por ciento, virilización y un paciente presentó clínica derivada de la hipocaliemía. Los métodos de diagnóstico básico utilizados fueron: estudios de funcionalidad, ecografía y TAC realizándose gammagrafía con MIBG, RNM o arteriografía en casos concretos. La incisión más habitual fue la lumbotomía en el 53 por ciento de las intervenciones. RESULTADOS: El postoperatorio osciló entre 7 y 23 días con una media de 11. Las complicaciones derivadas de la intervención aparecieron en el 38,4 por ciento de los pacientes intervenidos: esplenectomía, reintervención por sangrado, problemas derivados del control tensional, problemas vasculares (TIA,TVP), infección de herida quirúrgica y neumonía. El 50 por ciento de las masas resultaron feocromocitomas, el 10 por ciento carcinomas y el 5 por ciento adenomas. En el resto nos encontramos con tumores de la cresta neural, un quiste adrenal calcificado, un mielolipoma y una metástasis de primario renal CONCLUSIONES: Realizamos una revisión de los aspectos diagnósticos y terapéuticos de las masas suprarrenales (AU)

Angiofibroma juvenil de nasofaringe

Este es el reporte de un caso de un paciente de 14 años que acudió a consulta por epistasis y obstrucción, causado por un tumor, que ocupó la cavidad nasal y el seno maxilar izquierdo. Histopatológicamente fue diagnosticado como un angiofibroma juvenil, el cual fue totalmente removido con una rinotomía lateral, abordaje transpalatino y antrostomía de Caldwell-Luc